^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tevimbra (tislelizumab-jsgr) (PD1 inhibitor) + ociperlimab (BGB-A1217) (TIGIT inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer
Excerpt:
...Tumors with PD-L1 expressed in ≥ 50% tumor cells....
Trial ID:
Source:
Title:
Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors
Excerpt:
...Cohort 1: stage IV squamous NSCLC Cohort 2: stage IV non-squamous NSCLC Cohort 3: stage IV squamous or non-squamous NSCLC with PD-L1 positive....
Trial ID:
More C2 evidence
Source:
Title:
A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
Excerpt:
...Overall Survival (OS)`Overall Response Rate (ORR)`Duration of Response (DOR)`Time to death or distant metastasis (TTDM) as assessed by the investigator`Progression-Free Survival 2 (PFS2)`Number of participants experiencing Adverse Events (AEs)`Health Related Quality of Life (HRQoL) as assessed by European Organisation for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC-QLQ-C30)`Health Related Quality of Life (HRQoL)as assessed by Quality of Life Questionnaire-Lung Cancer 13 (QLQ-LC13)`Health Related Quality of Life (HRQoL) as assessed by European Quality of Life-5 Dimensions (EQ-5D-5L)`Serum concentration of ociperlimab`Serum concentration of tislelizumab`Immunogenic responses to BGB-A1217 as assessed by the detection of anti-drug antibodies (ADAs)`Immunogenic responses to Tislelizumab as assessed by the detection of anti-drug antibodies (ADAs)`Evaluate PD-L1 and TIGIT expression in archival and/or fresh tumor tissues...
Less C2 evidence
Source:
Title:
EP08.01-073 - AdvanTIG-105: Phase 1b Dose-Expansion Study of Ociperlimab plus Tislelizumab in Patients with Metastatic NSCLC
Published date:
07/12/2022
Excerpt:
The median study follow-up time was 15.9 weeks (range 6.1-47.6). All 36 patients were efficacy evaluable; the confirmed ORR was 22.2% (95% confidence interval [CI]: 10.1, 39.2) and the unconfirmed ORR was 44.4% (95% CI: 27.9, 61.9). The DCR was 88.9% (95% CI: 73.9, 96.9). The confirmed ORR in PD-L1 TC ≥ 50% (n=13) was 23.1%, while the confirmed ORR in PD-L1 TC 1-49% (n=23) was 21.7%. The treatment combination of ociperlimab 900 mg plus tislelizumab 200 mg IV Q3W was well tolerated and showed antitumor activity in patients with treatment-naïve metastatic squamous or non-squamous NSCLC with PD-L1 positive tumors (TC ≥ 1%).
